Cytomegalovirus reactivation after transplant is dangerous, and resistance or intolerance to ganciclovir-based therapy leaves clinicians with toxic fallback options. Livtencity (maribavir) offered a different target.
Maribavir inhibits the viral UL97 protein kinase, blocking CMV DNA replication, encapsidation, and nuclear egress through a target distinct from the DNA polymerase other antivirals attack. The oral tablet treats post-transplant CMV infection unresponsive to available therapy in patients 12 years and older weighing at least 35 kg.
Livtencity holds orphan designation with no generic competition and avoids the myelosuppression and nephrotoxicity that limit ganciclovir and foscarnet. Its oral route enables outpatient management, making it a natural comparator for refractory CMV programs in transplant medicine.
